Notably, several studies have demonstrated IL‐1R2 abnormal expression in various cancers, such as lung cancer (Fennell et al., 2014), prostate cancer (Jones et al., 2013), and adrenocortical cancer (Szabo et al., 2014). This evidence concerns the gene IL1R2 and prostate carcinoma.